Poor Agreement of Prostate Specific Antigen Doubling Times Calculated Using Ultrasensitive Versus Standard Prostate Specific Antigen Values: Important Impact on Risk Assessment
Keywords: prostatic neoplasms; postoperative period; prostate-specific antigen; tumor markers; biological; pharmacokinetics; BCR; biochemical recurrence; PSA; prostate specific antigen; PSADT; prostate specific antigen doubling time; RP; radical prostatectomy; SEAR